CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Inclusion Criteria: * Newly diagnosed with acute myelogenous leukemia (except acute promyelocytic leukemia) and has failed one or two prior standard induction attempts. Failure is defined as: * ≥ 30% bone marrow blasts with at least 20% cellularity at mid-cycle bone marrow biopsy or residual AML on subsequent\~ day 28 bone marrow biopsy by morphology, flow, PCR or FISH * Patients enrolling after only 1 failed induction attempt must meet at least one of the following additional eligibility criteria of high risk: ≥ 60 years of age adverse cytogenetics or molecular characteristics * AML that progressed out of myelodysplastic syndrome (MDS) is eligible if the patient did not receive treatment directed at the MDS * HLA-haploidentical related donor (aged 12 to 70 years) * ≥ 18, but \< 75 years of age * Karnofsky performance status ≥ 60% * Adequate organ function within 14 days of study registration (30 days for pulmonary and cardiac) as defined in section 4.5 * Ability to be off prednisone and other immunosuppressive drugs for at least 3 days prior to the NK cell infusion (excluding preparative regimen pre-meds) * No prior hematopoietic transplant * Not pregnant or lactating * Sexually active females of childbearing potential and males with partners of child bearing potential must agree to use birth control Exclusion Criteria: * Pregnant or lactating as the treatments used in this study includes drugs that are FDA Pregnancy Category D. * Acute leukemias of ambiguous lineage * AM…